ARTBIO Strengthens Leadership with Strategic Board Appointments to Advance Alpha Radioligand Therapies

ARTBIO, Inc., a clinical-stage radiopharmaceutical company at the forefront of developing alpha radioligand therapies (ARTs), has announced the addition of four distinguished members to its Board of Directors. This strategic move underscores the company's dedication to leveraging global expertise to accelerate the development of its groundbreaking cancer treatments. The new appointees bring a wealth of experience in biotech investments, healthcare strategy, pharmaceutical operations, and capital markets, positioning ARTBIO for its next phase of growth.

Among the new board members is Maha Katabi, Ph.D., CFA, a General Partner at Sofinnova Investments, whose extensive background in biotech investments and public company management will guide ARTBIO in optimizing its financial strategies. Dr. Katabi's involvement in the early investment syndicate at RayzeBio, later acquired by BMS, highlights her keen eye for transformative biotech ventures.

Robert Mittendorff, M.D., MBA, brings a unique blend of medical and business expertise to the board. As a General Partner and Head of Healthcare at B Capital Group, his insights will be invaluable in steering ARTBIO's program expansion. His previous roles at Merck and Boston Consulting Group further enrich the board's strategic depth.

Julie O’Neill, MBA, an independent director with a robust background in pharmaceutical manufacturing and operations, will contribute her operational excellence to ARTBIO's mission. Her leadership roles at Alexion Pharmaceuticals and Gilead Sciences, coupled with her board positions at several biotech firms, underscore her ability to drive operational success.

Gabe Gelman, with his extensive experience in equity capital markets at Goldman Sachs and current role at Baker Bros. Advisors LP, will bolster ARTBIO's financial strategies, ensuring the company's sustainable growth and innovation in the radiopharmaceutical space.

The transition of co-founder Roy Larsen, Ph.D., to the newly established Technical Advisory Board marks a pivotal moment for ARTBIO. Dr. Larsen's pioneering work in radiopharmaceuticals will continue to influence the company's scientific direction, ensuring that ARTBIO remains at the cutting edge of cancer therapy development.

ARTBIO's commitment to revolutionizing cancer treatment through its AlphaDirect technology and distributed manufacturing approach is further strengthened by these appointments. With its lead program, AB001, already in human trials for metastatic castration-resistant prostate cancer, ARTBIO is poised to make significant strides in the fight against cancer. For more information on ARTBIO's innovative approach to cancer care, visit https://www.artbio.com.